Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US10668149B2 · kind B2 · utility
13Cited by
13References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 22, 2016 |
| Grant date | Jun 2, 2020 |
| Priority date | — |
| Expiry date | Jun 22, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y302/01035
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.